Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brigatinib in Refractory ALK+ NSCLC
NCT02706626Phase 2Terminated
- Sponsor
- Criterium
- Start
- Mar 2017
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of brigatinib in non-small cell lung cancer (NSCLC) (3 cohorts), sponsored by Criterium. Primary endpoint: Objective Response Rate. Started Mar 2017; status: terminated.
02
Drugs
brigatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02706626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02706626.